# DESCRIPTION

## FIELD OF THE INVENTION

## BACKGROUND

## DESCRIPTION OF THE INVENTION

## EXAMPLES

### Example 1: Simultaneous Silencing of TGF-β1 and COX-2 Gene Expressions

### Example 2: Simultaneous Silencing of TGF-β1 and COX-2 Gene Expressions Resulted in Activation of Apoptosis of Fibroblasts/Myofibroblasts

### Example 3. HKP Enhances siRNA Delivery Into Human Hypertrophic Scar

### Example 4. HKP-Packaged TGF-β1/COX-2siRNA Reduces Size of Human Hypertrophic Scar

### Example 5. HKP (TGF-β1/COX-2siRNAs) Reduces Size of Human Skin Grafts

### Example 6. HKP (TGF-β1/COX-2siRNAs) Demonstrates a Novel Anti-Fibrotic Mechanism of Action

### Example 7. HKP (TGF-β1/COX-2 siRNAs) Induced Apoptotic Activities of the Fibroblast/Myofibroblasts In Vivo

### Example 8. HKP (TGF-β1/COX-2 siRNAs) Serves as a Novel Anti-Fibrotic Therapeutic Agent

## Discussion

## Materials and Methods

### siRNA Sequence Design and Selection

### Growth Inhibition In Vitro

### Nanoparticle Preparation

### Mouse

### Human Hypertrophic Scar and Skin Tissue Implant Models

### Therapeutic Evaluation with the Human Tissue Implant Models

### Statistical Analysis

